KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Payables (2016 - 2025)

Historic Payables for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $115.7 million.

  • Alnylam Pharmaceuticals' Payables rose 3088.39% to $115.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $115.7 million, marking a year-over-year increase of 3088.39%. This contributed to the annual value of $115.7 million for FY2025, which is 3088.39% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Payables is $115.7 million, which was up 3088.39% from $117.6 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Payables high stood at $117.6 million for Q3 2025, and its period low was $40.0 million during Q3 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Payables had a median value of $72.1 million in 2021 and averaged $72.7 million.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 10317.32% in 2021, then plummeted by 4340.22% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Payables (Quarter) stood at $73.4 million in 2021, then soared by 33.6% to $98.1 million in 2022, then plummeted by 43.4% to $55.5 million in 2023, then soared by 59.25% to $88.4 million in 2024, then surged by 30.88% to $115.7 million in 2025.
  • Its Payables stands at $115.7 million for Q4 2025, versus $117.6 million for Q3 2025 and $102.4 million for Q2 2025.